

CHO-K1/Human CT Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0040A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The Calcitonin Receptor (CTR or CALCR) is a G protein-coupled receptor activated by the hormone calcitonin. It is highly expressed on osteoclasts and also found in the kidneys, central nervous system, and some cancer cells. Its primary function is to mediate calcitonin's effects on bone and mineral metabolism, including potently inhibiting osteoclast-mediated bone resorption, regulating renal calcium and phosphate excretion, and potentially modulating pain perception in the CNS. Consequently, the calcitonin receptor is the direct target for drugs treating osteoporosis and Paget's disease of bone, with its analogs (e.g., salmon calcitonin) being widely used clinically.
Screeningbio’s CHO-K1/Human CT cell line overexpress CALCR and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | CALCR |
Accession Number | NM_001742 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![CHO-K1/Human CT Agonist Assay. CHO-K1/Human CT cells were treated with the reference agonist. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_99d4d01ac0514d51af3aad7f0b21b5b6~mv2.png/v1/fill/w_75,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_99d4d01ac0514d51af3aad7f0b21b5b6~mv2.png)
Target Background
The Calcitonin Receptor (CTR or CALCR) is a G protein-coupled receptor activated by the hormone calcitonin. It is highly expressed on osteoclasts and also found in the kidneys, central nervous system, and some cancer cells.
Its primary function is to mediate calcitonin's effects on bone and mineral metabolism, including potently inhibiting osteoclast-mediated bone resorption, regulating renal calcium and phosphate excretion, and potentially modulating pain perception in the CNS.
Consequently, the calcitonin receptor is the direct target for drugs treating osteoporosis and Paget's disease of bone, with its analogs (e.g., salmon calcitonin) being widely used clinically.